Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 45

Sort by

Sort Order Select

Journal Articles

Combined Ibrutinib and Venetoclax in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

Blood (2019) 134 (Supplement_1): 359.

https://doi.org/10.1182/blood-2019-131732

Published: 2019

Journal Articles

Clinical Outcomes of Non-Hodgkin Lymphoma Patients on Acalabrutinib Including Off-Label Utilization

Esin C. Namoglu, B.S., Mitchell E. Hughes, PharmD, Daniel J. Landsburg, MD, Stephen J. Schuster, MD, Jakub Svoboda, MD, Elise A. Chong, MD, James N. Gerson, MD, Stefan K. Barta, MD MRCP, MS, Sunita Dwivedy Nasta, MD

Blood (2019) 134 (Supplement_1): 5261.

https://doi.org/10.1182/blood-2019-130039

Published: 2019

Journal Articles

Concurrent Treatment of VEGFR Tyrosine Kinase Inhibitors (TKIs) and Factor Xa Inhibitors Is Associated with Increased Bleeding Risks

Sandip Patel, MBBS, Tiffany George, MD, Tzu-Fei Wang, MD MPH, Sherry Mori Vogt, Pharm D, Edmund Folefac, MD, Ming Yin, MD

Blood (2019) 134 (Supplement_1): 3681.

https://doi.org/10.1182/blood-2019-130465

Published: 2019

Journal Articles

Hepatitis C Virus Infection, but Not Hepatic Iron Overload Is the Dominant Risk Factor for the Manifestation of Hepatocellular Carcinoma Among Greek Thalassemic Patients

Blood (2018) 132 (Supplement 1): 2347.

https://doi.org/10.1182/blood-2018-99-119731

Published: 2018

Journal Articles

Risk of Second Primary Malignancies in Chronic Lymphocytic Leukemia

Anuhya Kommalapati, MD, Sri Harsha Tella, MD, Gaurav Goyal, MBBS

Blood (2018) 132 (Supplement 1): 3581.

https://doi.org/10.1182/blood-2018-99-120123

Published: 2018

Journal Articles

Solid Tumors in Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis: A Study on 2220 Patients

Blood (2018) 132 (Supplement 1): 3039.

https://doi.org/10.1182/blood-2018-99-115318

Published: 2018

Journal Articles

Cancer Incidence in Sickle Cell Disease:an Institutional Experience

Shivi Jain, MD, Andrew Srisuwananukorn, MD, Santosh L. Saraf, MD, Xu Zhang, PhD, Jin Han, PharmD, PhD, Michel Gowhari, DO, Robert E. Molokie, MD, Victor R. Gordeuk, MD

Blood (2018) 132 (Supplement 1): 1087.

https://doi.org/10.1182/blood-2018-99-115508

Published: 2018

Journal Articles

Survival Outcome of Secondary Solid Cancer in Patients with Chronic Myeloid Leukemia

Hamzah Munir Alqam, MD, Hagop M. Kantarjian, MD, Dai Chihara, MDPhD, Koji Sasaki, MD, Elias J. Jabbour, MD, Jorge E. Cortes, MD

Blood (2017) 130 (Supplement 1): 1623.

https://doi.org/10.1182/blood.V130.Suppl_1.1623.1623

Published: 2017

Journal Articles

A Novel Immunoblot Assay to Detect Contact Activation in Patients with Cancer

Dewen You, PhD, Victor Chatterjee, MD, Mohamed Samour, MBBS, Suman Kundu, MBA, Alvin H. Schmaier, MD, Alok A. Khorana, MD, Keith McCrae, MD

Blood (2017) 130 (Supplement 1): 2385.

https://doi.org/10.1182/blood.V130.Suppl_1.2385.2385

Published: 2017

Journal Articles

Determination of Red Blood Cell Alloimmunization Rates in Transfused Patients with Hematologic and Oncologic Malignancies

Mariette Asare, MD, Jeanne E Hendrickson, MD, Christopher A Tormey, MD

Blood (2016) 128 (22): 1463.

https://doi.org/10.1182/blood.V128.22.1463.1463

Published: 2016

Journal Articles

Novel Near-Infrared Heptamethine Carbocyanine Fluorescent Dye-Cisplatin Conjugate Demonstrates Significant Antitumor Activity and Overcomes Cisplatin Resistance in MYC-Driven TP53 Mutated Aggressive B-Cell Burkitt's Lymphoma

Stefan Mrdenovic, MD, Yi Zhang, PhD, Yin Lijuan, MD, PhD, Wen-Chin Huang, PhD, Gina Chia-Yi Chu, PhD, Ruoxiang Wang, MD, PhD, Jason Bojang Wu, PhD, Ronald Paquette, MD, Haiyen E. Zhau, PhD, Leland W. K. Chung, PhD

Blood (2016) 128 (22): 4173.

https://doi.org/10.1182/blood.V128.22.4173.4173

Published: 2016

Journal Articles

Prevalence of Extramedullary Hematopoiesis, Vertebral, Hepatic and Splenic Hemangioma and Renal Cyst Among Thalassaemic Patients: A Retrospective Study from the Myocardial Iron in Thalassemia (MIOT) Network

Alessia Pepe, Antonella Meloni, Alessandra Briatico Vangosa, Fabrizia Terrazzino, Maria Giovanna Neri, Domenico Maddaloni, Gaetano Roccamo, Sabrina Armari, Aurelio Maggio, MD, Cristina Salvatori, Vincenzo Positano, Paolo Ricchi

Blood (2015) 126 (23): 2154.

https://doi.org/10.1182/blood.V126.23.2154.2154

Published: 2015

Journal Articles

Clinicopathologic Features and Survival Outcomes of Secondary Mantle Cell Lymphoma after Primary Solid Malignancy

Raji Shameem, MD, Muhammad Saad Hamid, MD, Nasheed Mohammad Hossain, MD, Jeffrey Mufson, MD, Patricia L. Kropf, MD

Blood (2015) 126 (23): 2652.

https://doi.org/10.1182/blood.V126.23.2652.2652

Published: 2015

Journal Articles

Second Cancers Affect the Clinical Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Frontline FCR-Based Therapy.

Long Xuan Trinh, MD, Young Kwang Chae, MD, MPH, Preetesh Jain, MD, DM, PhD, Susan Lerner, MS, Ohad Benjamini, MD, Xuemei Wang, MS, Michael J. Keating, MD

Blood (2012) 120 (21): 2900.

https://doi.org/10.1182/blood.V120.21.2900.2900

Published: 2012

Journal Articles

Identification of a Human Endogenous Retrovirus Type-E (HERV-E) Envelope with Selective Expression in Clear Cell Kidney Cancer That Is Immunogenic in Vitro.

Elena Cherkasova, Quinn Weisman, BS, Sachiko Kajigaya, PhD, Yoshiyuki Takahashi, MD, PhD, Robert N Reger, Nanae Harashima

Blood (2012) 120 (21): 3015.

https://doi.org/10.1182/blood.V120.21.3015.3015

Published: 2012

Journal Articles

Sunitinib and Intensive Chemotherapy in Patients with Acute Myeloid Leukemia and Activating FLT3 Mutations: Results of the AMLSG 10-07 Study (ClinicalTrials.gov No. NCT00783653)

Walter Fiedler, MD, Sabine Kayser, Maxim Kebenko, M.D., Jürgen Krauter, MD, PhD, Helmut R. Salih, M.D., Katharina Götze, M.D., Daniela Späth, MSc, Gudrun Göhring, MD, Veronica Teleanu, MD, Konstanze Döhner, MD, Arnold Ganser, Hartmut Döhner, MD, Richard F Schlenk, MD

Blood (2012) 120 (21): 1483.

https://doi.org/10.1182/blood.V120.21.1483.1483

Published: 2012

Journal Articles

Characterization of Peripheral B Cells Expressing CLL-Associated Receptor Tyrosine Kinase ROR1 in Healthy Donors

Julia Milleck, Karl-Anton Kreuzer, Dr. med., Mario Assenmacher, PhD, Jürgen Schmitz, PhD, Peter S Jähn, PhD

Blood (2012) 120 (21): 1787.

https://doi.org/10.1182/blood.V120.21.1787.1787

Published: 2012

Journal Articles

Improved Survival After Allogeneic Hematopoietic Stem Cell Transplantation for Metastatic Renal Cancer Associated with Homozygosity for the HLA-G 14 Base-Pair Deletion Polymorphism: An EBMT STWP Study

Benedetta Mazzi, BSc, Roberto Crocchiolo, MD, Didier Blaise, MD, Lisbeth Barkholt, MD, Jacques-Olivier Bay, MD, PhD, Rocco Pastano, MD, Margherita Torchio, PhD, Stefania Trinca, DM, Jacopo Peccatori, MD, Fabio Ciceri, MD, Katharina Fleischhauer, MD, Marco Bregni, MD

Blood (2012) 120 (21): 4667.

https://doi.org/10.1182/blood.V120.21.4667.4667

Published: 2012

Journal Articles

Second Cancers After Treatment with Stanford V Regimen in Eastern Cooperative Oncology Group (ECOG) Pilot Study E1492 At a Median Follow up of 17 Years

Ranjana H. Advani, MD, Hailun Li, MS, Richard T. Hoppe, MD, Nancy L. Bartlett, MD, John M. Bennett, MD, Donna S. Neuberg, ScD, Peter A Cassileth, MD, Brad S. Kahl, M.D., Sandra J. Horning, M.D.

Blood (2012) 120 (21): 4779.

https://doi.org/10.1182/blood.V120.21.4779.4779

Published: 2012

Journal Articles

Novel Homozygous VHL Mutation in Exon 2 (413C>T:P138L) Is Associated with Congenital Polycythemia, Elevated Level of RUNX1/AML1 Transcript, but Not with the Cancer.

Lucie Piterkova, PhD, Felipe R Lorenzo V, M.D., PhD., Hari Vankalayapati, MPharm., PhD., Richard A. Drachtman, MD, Josef T. Prchal, MD

Blood (2012) 120 (21): 2081.

https://doi.org/10.1182/blood.V120.21.2081.2081

Published: 2012

NARROW

Combined Ibrutinib and Venetoclax in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

Clinical Outcomes of Non-Hodgkin Lymphoma Patients on Acalabrutinib Including Off-Label Utilization

Concurrent Treatment of VEGFR Tyrosine Kinase Inhibitors (TKIs) and Factor Xa Inhibitors Is Associated with Increased Bleeding Risks

Hepatitis C Virus Infection, but Not Hepatic Iron Overload Is the Dominant Risk Factor for the Manifestation of Hepatocellular Carcinoma Among Greek Thalassemic Patients

Risk of Second Primary Malignancies in Chronic Lymphocytic Leukemia

Solid Tumors in Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis: A Study on 2220 Patients

Cancer Incidence in Sickle Cell Disease:an Institutional Experience

Survival Outcome of Secondary Solid Cancer in Patients with Chronic Myeloid Leukemia

A Novel Immunoblot Assay to Detect Contact Activation in Patients with Cancer

Determination of Red Blood Cell Alloimmunization Rates in Transfused Patients with Hematologic and Oncologic Malignancies

Novel Near-Infrared Heptamethine Carbocyanine Fluorescent Dye-Cisplatin Conjugate Demonstrates Significant Antitumor Activity and Overcomes Cisplatin Resistance in MYC-Driven TP53 Mutated Aggressive B-Cell Burkitt's Lymphoma

Prevalence of Extramedullary Hematopoiesis, Vertebral, Hepatic and Splenic Hemangioma and Renal Cyst Among Thalassaemic Patients: A Retrospective Study from the Myocardial Iron in Thalassemia (MIOT) Network

Clinicopathologic Features and Survival Outcomes of Secondary Mantle Cell Lymphoma after Primary Solid Malignancy

Second Cancers Affect the Clinical Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Frontline FCR-Based Therapy.

Identification of a Human Endogenous Retrovirus Type-E (HERV-E) Envelope with Selective Expression in Clear Cell Kidney Cancer That Is Immunogenic in Vitro.

Sunitinib and Intensive Chemotherapy in Patients with Acute Myeloid Leukemia and Activating FLT3 Mutations: Results of the AMLSG 10-07 Study (ClinicalTrials.gov No. NCT00783653)

Characterization of Peripheral B Cells Expressing CLL-Associated Receptor Tyrosine Kinase ROR1 in Healthy Donors

Improved Survival After Allogeneic Hematopoietic Stem Cell Transplantation for Metastatic Renal Cancer Associated with Homozygosity for the HLA-G 14 Base-Pair Deletion Polymorphism: An EBMT STWP Study

Second Cancers After Treatment with Stanford V Regimen in Eastern Cooperative Oncology Group (ECOG) Pilot Study E1492 At a Median Follow up of 17 Years

Novel Homozygous VHL Mutation in Exon 2 (413C>T:P138L) Is Associated with Congenital Polycythemia, Elevated Level of RUNX1/AML1 Transcript, but Not with the Cancer.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only